Takeda Pharmaceutical Company Limited

Koji Ikedou

Satoru Oi

Hiroyuki Tawada

Masaki Ogino

Hironobu Maezaki

Yoshihiro Banno

Taihei Yamane

Koji Takeuchi

A compound represented by the formula wherein ring A is an optionally substituted 5- to 10-membered aromatic ring; Rand Rare the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X and Y are the same or different and each is a bound, &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;SO&#x2014;, &#x2014;SO?2#191- or &#x2014;NR&#x2014; (Ris a hydrogen atom or an optionally substituted hydrocarbon group); and L is a divalent hydrocarbon group, or a salt thereof shows a superior peptidase-inhibitory activity and is useful as a prophylactic or therapeutic agent of diabetes and the like. 

Fused heterocyclic compounds as peptidase inhibitors

The present invention provides a compound of the formula: wherein ring A is an optionally substituted 5 to 10-membered aromatic ring; Rand Rare the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a bond and the like; and L is a divalent hydrocarbon group, and a salt thereof, except 3-(aminomethyl)-2,6,7-trimethyl-4-phenyl-1(2H)-isoquinolinone, 3-(aminomethyl)-2-methyl-4-phenyl-1(2H)-isoquinolinone, 3-(aminomethyl)-6-chloro-2-methyl-4-phenyl-1(2H)-isoquinolinone and 3-(aminomethyl)-2-isopropyl-4-phenyl-1(2H)-isoquinolinone. The compound shows a superior peptidase-inhibitory activity and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

Fused heterocyclic compounds

Growing community of inventors

Himeji, Japan

Koji Ikedou